VenBio related stories
All articles and analysis
Worldwide fundraising briefsFrom Mucker in LA to Atomico in the UK, a recap of worldwide fundraising news
venBio collects $288 mln toward second venture fundHealthcare investment firm venBio Partners LLC raised $288 million from 22 LPs toward a $303 million venture fund, according to an SEC filing.
- Apellis Pharmaceuticals raises $47.1 in Series D financing
Drug developer Apellis Pharmaceuticals Inc raised $47.1 million in Series D preferred stock financing. The round was led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund. Earlier this month Apellis withdrew its plans for an initial public offering, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1492422/000119312516453827/d130104drw.htm
- Checkmate Pharma raises $20 mln
Checkmate Pharmaceuticals said Tuesday that it raised $20 million in Series A financing from Sofinnova Ventures and venBio. Checkmate is a biopharmaceutical company aimed at developing cancer immunotherapies.
- Haines, von Emster named Abingworth joint Managing Partners
Abingworth said Monday that Tim Haines and Kurt von Emster were named joint Managing Partners. Stephen Bunting, who has held the Managing Partner role since 2002, will become Chairman. The changes are effective immediately.
- Precision BioSciences raises $25.6 mln
Precision BioScience said Monday it closed a $25.6 million Series A round led by venBIO. Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two well-known public market investors also participated. Research Triangle Park, North Carolina-based Precision BioSciences is a genome editing company.
Top ten VC deals done in Canada in 2014The Canadian Venture Capital & Private Equity Association (CVCA) and research partner Thomson Reuters will in February 2015 publish their full report on Canadian venture capital market activity in 2014. In the meantime, peHUB Canada has compiled a list of the likely top 10 (disclosed) financings completed this year.
- Abingworth names von Emster a partner
Abingworth said Friday that Kurt von Emster was named a partner effective January 5th. He will be based in Menlo Park and will help source and manage deals in early-stage and late-stage venture capital, venture growth and public market investments including VIPEs. London-based Abingworth is an investment group that focuses on life sciences and healthcare.
- VC-backed Solstice Biologics hires new president/CEO and CFO
San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm's board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer's biotherapeutic and bioinnovation center.
- Teva agrees to buy VC-backed Labrys for up to $825 mln
sraeli pharmaceutical company Teva Pharmaceutical Industries has agreed to acquire Labrys Biologics for $200 million in upfront payment in cash as well as up to $625 million in payments based on achievement of certain pre-launch milestones. Based in San Mateo, Calif., Labrys is a biotech firm focused on treating migraine. It was backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.